Personalized Immunotherapy

One of the most exciting segments of today’s talk centers on neoantigen vaccines. Unlike broad-spectrum chemotherapy, these mRNA sequences are coded specifically to a patient’s tumor profile.

The Three-Step Process:

1. Biopsy & Sequencing: Identifying unique mutations within the patient’s tumor.

2. Algorithm Selection: Using AI to predict which neoantigens will trigger the strongest immune response.

3. Synthesis: Printing the mRNA strand and delivering it via lipid nanoparticles (LNPs).

Resources Mentioned in this Episode

If you want to dive deeper into the data mentioned by Dr. Jenkins, check out these peer-reviewed resources:

• The Lancet: Advances in Lipid Nanoparticle Delivery Systems (2025 Study)

• PharmaWorld Index: Top 10 Biotech Startups to Watch in the mRNA Space

• Whitepaper: The Impact of Decentralized Clinical Trials on Patient Retention

Episode Credits & Guest Info

Guest: Dr. Sarah Jenkins is the Chief Science Officer at Genomix Bio. She has over 20 years of experience in molecular biology and has authored over 50 publications in Nature Medicine.

Host: Mark Sterling, Senior Pharma Analyst.

Subscribe to our newsletter to receive the full transcript and a weekly digest of the biggest moves in the pharmaceutical industry.